Summary of COVID-19 lufotrelvir studies

1. Grandits et al., PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

58 patient lufotrelvir late treatment RCT: 22% higher mortality (p=0.77) and 44% higher hospital discharge (p=0.11).
RCT 58 patients showing no significant differences with lufotrelvir. This is a 2021 study which has not been published yet. Results were made available on clinicaltrials.gov in 2024.
Feb 2024, NCT05780541, https://clinicaltrials.gov/study/NCT05780541, https://c19p.org/grandits